Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.48 |
| ▸ | ACACA | Q13085 | 9/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25548557 | 0.90 | SUV39H2 (0.50) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL24000748 | 0.88 | CKS1B (0.55) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL25546714 | 0.81 | ENPP1 (0.52) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL2385162 | 0.78 | CKS1B (0.49) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL16449186 | 0.76 | CKS1B (0.52) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL23107657 | 0.75 | ACACB (0.56) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL30376168 | 0.75 | CKS1B (0.52) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL16449187 | 0.73 | CKS1B (0.50) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL3436642 | 0.73 | CKS1B (0.59) | ACACBACACACKS1BSKP1SKP2 | |
| SCHEMBL16162195 | 0.73 | MEN1 (0.51) | CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | ENPP1, ENPP3, PPA1 | ACACB 3835/4885ACACA 3344/4885CKS1B 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.